Hutch News

Stories tagged 'Juno Therapeutics'

'Results you just don't expect to see': Many blood cancer patients in complete remission after immunotherapy

High rates of complete remission reported in patients with advanced blood cancers in preliminary results from ongoing immunotherapy trial

Dec. 7, 2015 | By Susan Keown / Fred Hutch News Service

Many patients with late-stage blood cancers receiving an experimental T-cell therapy went into complete remission, according to preliminary research results from a Fred Hutchinson Cancer Research Center trial presented this week at the annual meeting of the American Society of Hematology.

View story >


Immunotherapy for pancreatic cancer boosts survival more than 75 percent in mice, study finds

Therapy using engineered immune cells offers promise for the ‘disease that desperately needs something new’

Oct. 29, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

A certain type of immunotherapy can boost survival from the nearly-always deadly pancreatic cancer by more than 75 percent in mice, a new study finds.

View story >


Why cancer research needs business development – now more than ever

Meet Fred Hutch’s Dr. Niki Robinson, the woman who’s helping make it happen

July 24, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Nonprofit cancer research centers like the Hutch need business partnerships to get discoveries into the clinic faster. Meet the new VP who's helping make it happen.

View story >


'A tidal wave coming': Xconomy Forum focuses on promising treatments

Immunotherapy a key topic at sold-out discussion on the role of biotech in Seattle

May 7, 2015 | By Bill Briggs / Fred Hutch News Service

The word “cure” has long been overused, but the promise of immunotherapy as an anti-cancer weapon means it’s indeed the right time to start using it, said Dr. D. Gary Gilliland, president and director of Fred Hutch, at an Xconomy Forum held at the Hutch on Wednesday.

View story >


Three cancer research powerhouses form immunotherapy startup

Fred Hutch, Memorial Sloan-Kettering and Seattle Children’s Research Institute join to launch Juno Therapeutics

Dec. 3, 2013 | By Deborah Bach

Fred Hutch is advancing its legacy in immunotherapy by means of a new Seattle biotechnology company -- Juno Therapeutics -- that is a unique collaboration among scientists at the Hutch, Memorial Sloan-Kettering Cancer Center in New York and Seattle Children’s Research Institute.

View story >


Frequently asked questions about Juno Therapeutics

Dec. 3, 2013

View story >


For the Media


GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers


Fred Hutch News

Get updates via email.